News Search Results
Apr 03, 2024, 10:00 ET New England Biolabs® opens subsidiary in the Republic of Korea
NEB continues to expand its product offerings into areas related to PCR, gene expression, sample preparation for next generation sequencing, synthetic biology, glycobiology, epigenetics and RNA analysis. Additionally, NEB is focused on strengthening alliances that enable new technologies to reach key
More news about: New England Biolabs, Inc.
Apr 03, 2024, 07:02 ET Prozomix and Ginkgo Bioworks Collaborate on Next-Gen Enzyme Development for Sustainable API Manufacturing
and other expectations, and to identify and realize additional business opportunities, (iii) the risk of downturns in demand for products using synthetic biology, (iv) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (v) changes to the biosecurity industry,
More news about: Ginkgo Bioworks
Apr 02, 2024, 10:40 ET BCC Research Reveals Top Ten Suppliers of Synthetic Biology Technology in 2024
Learn More. Top Ten Suppliers of Synthetic Biology Technology Market Drivers Increasing Scope of Synthetic Biology in Healthcare Applications: Synthetic biology has emerged as a promising avenue within healthcare, with applications spanning
More news about: BCC Research LLC
Apr 02, 2024, 08:00 ET Cultivarium and ATCC Support iGEM Teams Striving to Advance the Field of Synthetic Biology
horizons of synthetic biology research. iGEM teams will gain access to a rich selection of non-model microbes curated by ATCC and Cultivarium's expertise and technologies for new frontiers in bioengineering. During the past 20 years, 70,000+ iGEM participants have entered 5,000 synthetic biology projects
More news about: Cultivarium
Apr 02, 2024, 07:02 ET Ginkgo Bioworks Acquires Modulus Therapeutics' Cell Therapy Assets to Strengthen Next-Gen CAR Designs
and other expectations, and to identify and realize additional business opportunities, (iii) the risk of downturns in demand for products using synthetic biology, (iv) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (v) changes to the biosecurity industry,
More news about: Ginkgo Bioworks
Apr 01, 2024, 10:00 ET New England Biolabs® Commemorates 50th Anniversary with Series of Events to Celebrate Customers
NEB continues to expand its product offerings into areas related to PCR, gene expression, sample preparation for next generation sequencing, synthetic biology, glycobiology, epigenetics and RNA analysis. Additionally, NEB is focused on strengthening alliances that enable new technologies to reach key
More news about: New England Biolabs, Inc.
Mar 29, 2024, 08:40 ET 73% CNS ORR! FDA Granted ODD to Utidelone Injectable (UTD1) from Biostar Pharma for the Treatment of Breast Cancer Brain Metastasis
29, 2024 /PRNewswire/ -- Biostar Pharma, Inc., the U.S. subsidiary of Beijing Biostar Pharmaceuticals Co., Ltd. which is a synthetic biology driven biopharma company focusing on the development and commercialization of innovative oncology drugs, announced today that their core pipeline
More news about: Beijing Biostar Pharmaceuticals Co., Ltd.
Mar 28, 2024, 07:02 ET Ginkgo Bioworks Awarded DARPA Funding to Produce Novel Proteins to Control Ice in Extreme Cold Weather Environments
proteins is possible thanks to Ginkgo's unique and differentiated data assets. Biology offers us a myriad of ways to adapt to our environment, and synthetic biology allows us to tap into nature's capabilities and apply them to our own needs. We look forward to the products that the ICE program generates, which
More news about: Ginkgo Bioworks
Mar 27, 2024, 08:45 ET Integrated DNA Technologies Unveils New Custom Vector Onboarding Tool to Optimize Gene Synthesis
safe."With gene synthesis accelerating research and propelling the design, build, test, and learn cycle that underpins innovations in synthetic biology, efficiency and speed are increasingly becoming more critical to researchers," said Sandy Ottensmann, VP/GM of
More news about: Integrated DNA Technologies
Mar 27, 2024, 07:02 ET AQUA Cultured Foods Partners with Ginkgo Bioworks to Optimize Alt-Seafood Production
and other expectations, and to identify and realize additional business opportunities, (iii) the risk of downturns in demand for products using synthetic biology, (iv) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (v) changes to the biosecurity industry,
More news about: Ginkgo Bioworks
Mar 26, 2024, 07:02 ET Imagindairy and Ginkgo Bioworks Collaborate to Develop and Produce Animal-Free Non-Whey Dairy Proteins
and other expectations, and to identify and realize additional business opportunities, (iii) the risk of downturns in demand for products using synthetic biology, (iv) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (v) changes to the biosecurity industry,
More news about: Ginkgo Bioworks
Mar 21, 2024, 08:30 ET 100% CBR! FDA Granted ODD to Biostar Pharma's Utidelone Capsule (UTD2) for the Treatment of Gastric Cancer
2024 /PRNewswire/ -- Biostar Pharma, Inc., the U.S. subsidiary of Beijing Biostar Pharmaceuticals Co., Ltd. which is a synthetic biology driven biopharma company focusing on the development and commercialization of innovative oncology drugs, announced today that their key pipeline
More news about: Beijing Biostar Pharmaceuticals Co., Ltd.
Mar 20, 2024, 21:45 ET Immuno-Oncology Therapies: In-Depth Analysis of the Rapidly Evolving Landscape in Next-Generation Cancer Treatment
Growth Opportunity 1: Combination ImmunotherapiesGrowth Opportunity 2: Precision OncologyGrowth Opportunity 3: Advanced Synthetic Biology PlatformsGrowth Opportunity 4: Organoids and Organ-on-Chip ModelsKey Topics Covered: Growth Environment:
More news about: Research and Markets
Mar 12, 2024, 08:15 ET GenScript Biotech Announces 2023 Annual Results with a Five-Year CAGR stands at 30%
by 30-40%. In order to better address R&D needs for enzymes and synthetic biology, the R&D team of Bestzyme has expanded by about 20%. In terms of the synthetic biologic pipeline, Bestzyme's first 2 synthetic biology candidates, natural sweeteners and lactoferrin are making promising results
More news about: GenScript Biotech Corporation
Mar 12, 2024, 07:01 ET CDC Traveler-based Genomic Surveillance Program to Expand to Two New US International Airports in Miami and Chicago
and other expectations, and to identify and realize additional business opportunities, (iii) the risk of downturns in demand for products using synthetic biology, (iv) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (v) changes to the biosecurity industry,
More news about: Ginkgo Bioworks
Mar 08, 2024, 08:00 ET Dr. David Liu Joins GenScript's Scientific Advisory Board to Guide Company's Innovation Strategy
said Sherry Shao, Rotating Chief Executive Officer of GenScript. "His expertise in genome editing, chemistry, and synthetic biology will provide invaluable insights as we continue to develop and provide innovative tools and solutions, particularly in the area of genome engineering."
More news about: GenScript Biotech Corporation
Mar 07, 2024, 07:30 ET Moligo Technologies Appoints John Kuijpers as Chief Business Officer
has tremendous potential to grow its co-development business for new biotherapeutics and to enable new applications in many industries, from synthetic biology to agriculture." About Moligo TechnologiesMoligo Technologies produces long, ultrapure, single-stranded, complex DNA at
More news about: Moligo Technologies
Mar 05, 2024, 12:12 ET Synthetic biology market size to grow by USD 28.25 billion from 2022 to 2027, the evolving regulatory framework around synthetic biology is the market trend, Technavio
global synthetic biology market size is estimated to grow by USD 28.25 billion from 2022 to 2027, according to Technavio. The market is estimated to grow at a CAGR of 25.6% during the forecast period. The evolving regulatory framework around synthetic biology is a
More news about: Technavio
Mar 01, 2024, 07:00 ET PRECISIO BIOTIX THERAPEUTICS ACQUIRES LONDON-HEADQUARTERED CC BIO, ADDING WORLD-CLASS ANTIBACTERIAL PLATFORM AND TOP SCIENTISTS
BIOCC Bio is an early stage bioinformatics company based in London, United Kingdom. Utilizing deep expertise in synthetic biology and microbiology, CC Bio has developed Zeus™, a pioneering endolysin design platform which complements Precisio Biotix's existing LysiThru™ endolysin
More news about: Precisio Biotix Therapeutics, Inc.
Feb 29, 2024, 17:01 ET Ginkgo Bioworks Reports Fourth Quarter and Full Year 2023 Financial Results
and other expectations, and to identify and realize additional business opportunities, (iii) the risk of downturns in demand for products using synthetic biology, (iv) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (v) changes to the biosecurity industry,
More news about: Ginkgo Bioworks
Feb 28, 2024, 07:03 ET Ginkgo Bioworks Provides Compensation Information Related to Recent Acquisitions
and other expectations, and to identify and realize additional business opportunities, (iii) the risk of downturns in demand for products using synthetic biology, (iv) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (v) changes to the biosecurity industry,
More news about: Ginkgo Bioworks
Feb 28, 2024, 07:02 ET Ginkgo Bioworks Acquires Reverie Labs Platform, Enhancing AI-Driven Drug Discovery Capabilities for Customer Programs
and other expectations, and to identify and realize additional business opportunities, (iii) the risk of downturns in demand for products using synthetic biology, (iv) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (v) changes to the biosecurity industry,
More news about: Ginkgo Bioworks
Feb 28, 2024, 07:02 ET Ginkgo Bioworks Acquires Proof Diagnostics, Growing Gene Editing Service Offerings for its Customers
and other expectations, and to identify and realize additional business opportunities, (iii) the risk of downturns in demand for products using synthetic biology, (iv) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (v) changes to the biosecurity industry,
More news about: Ginkgo Bioworks
Feb 28, 2024, 07:02 ET Ginkgo Bioworks Acquires Patch Biosciences, Expanding Suite of Genetic Medicine Capabilities Available to Customers
and other expectations, and to identify and realize additional business opportunities, (iii) the risk of downturns in demand for products using synthetic biology, (iv) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (v) changes to the biosecurity industry,
More news about: Ginkgo Bioworks
Feb 28, 2024, 07:01 ET Ginkgo Technology Network Launches, Providing an Integrated R&D Experience with Capabilities from Over 25 Inaugural Partners
bit.bio is a synthetic biology company focused on human cells, advancing medicine and enabling curative treatments. bit.bio's opti-ox™ precision cell programming technology
More news about: Ginkgo Bioworks